Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Author: Global Cancer Consortium
Inovio Pharmaceuticals (AMEX:INO) won the Edward Jenner Poster Award First Prize for its research to develop a therapeutic, synthetic vaccine for cancer.
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his new column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his new column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
OneMedRadio interviewed Tom Moore, CEO and Chairman of the Board of Directors of Advaxis [OTC:ADXS]. He discusses the company’s novel immunotherapy technology.
The weather is cooling, but the health industry is heatings things up. OneMedSentinel is pleased to bring you another round of stories and interviews with some of the most promising companies and technologies, as well as innovative approaches to funding the growth economy. In this issue: Tom Moore, CEO of Advaxis [ADXS] speaks confidently about his technology’s ability to ensure immunity from certain cancers. Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his new column “This Week In Diagnostics”. Peter has over 30 years experience as a scientist, science…
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business. Peter has over 30 years experience as a scientist, science journalist, and publisher.
OneMedSentinel continues coverage of some of the most promising companies and technologies, as well as innovative approaches to funding the growth economy. In this issue: Rodman and Renshaw gears up for their 13th Annual Global Investment Conference. David Strupp discusses the firm and why it’s annual conference has become the world’s biggest and most anticipated next to JP Morgan’s. Wound Management [WNDM] President, Deborah Jenkins Hutchinson discusses the company’s plan to become cash flow positive and profitable within the next year. The outlook is promising with their recent distribution agreement in place for CellerateRX. Other interviews: Verisante Technologies [VRS] CEO,…